SCHIRONE, Alessio
 Distribuzione geografica
Continente #
NA - Nord America 343
EU - Europa 155
AS - Asia 97
AF - Africa 3
SA - Sud America 1
Totale 599
Nazione #
US - Stati Uniti d'America 339
IT - Italia 56
PL - Polonia 44
CN - Cina 37
SG - Singapore 37
GB - Regno Unito 13
DE - Germania 11
ID - Indonesia 10
UA - Ucraina 9
TR - Turchia 8
SE - Svezia 6
BE - Belgio 5
FI - Finlandia 5
CA - Canada 4
VN - Vietnam 4
EG - Egitto 2
LT - Lituania 2
RO - Romania 2
AL - Albania 1
BR - Brasile 1
IN - India 1
NL - Olanda 1
SD - Sudan 1
Totale 599
Città #
Warsaw 44
Fairfield 38
Singapore 34
Santa Clara 31
Chandler 30
Houston 25
Woodbridge 25
Ann Arbor 22
Ashburn 21
Seattle 18
Jacksonville 14
Wilmington 12
Bologna 10
Cambridge 10
Jakarta 10
Ferrara 9
Nanjing 9
Izmir 8
Milan 8
New York 6
Princeton 6
Shanghai 6
Beijing 5
Brussels 5
Helsinki 5
Boardman 4
Dong Ket 4
Falkenstein 3
Guangzhou 3
London 3
Baldissero Torinese 2
Cairo 2
Frosolone 2
Gualtieri 2
Jinan 2
Los Angeles 2
Nanchang 2
Ottaviano 2
Ottawa 2
Shenyang 2
Toronto 2
Ancona 1
Arcene 1
Bacau 1
Brooklyn 1
Changsha 1
Dearborn 1
Delhi 1
Falls Church 1
Hangzhou 1
Islington 1
Mossoró 1
Mountain View 1
Nave 1
Norwalk 1
Nuremberg 1
Redmond 1
Redwood City 1
Rome 1
San Diego 1
San Mateo 1
Tirana 1
Wandsworth 1
Washington 1
Zhengzhou 1
Totale 474
Nome #
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy 171
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 104
Core needle biopsy in invasive breast cancer prognostic/predictive power: concordance with surgical speciemen and impact of immunophenotypes 98
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 85
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 64
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 38
The Value of Semiquantitative Parameters Derived from 18F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes of Breast Cancer 35
Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer 22
ErbB2‐NOTCH1 axis controls autophagy in cardiac cells 10
Totale 627
Categoria #
all - tutte 3.997
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.997


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202034 0 0 0 0 0 0 8 6 5 7 2 6
2020/2021140 5 9 7 12 5 10 9 17 15 27 17 7
2021/202254 4 8 5 3 1 1 7 3 2 5 3 12
2022/202376 8 8 3 7 8 10 5 11 10 1 5 0
2023/202476 1 12 4 1 7 11 2 2 1 6 16 13
2024/2025112 6 12 23 11 30 30 0 0 0 0 0 0
Totale 627